CEPI Backs Phase 3 Trial for Moderna Pandemic Flu Vaccine

Industry Insights from Next Move Strategy Consulting

As global health systems continue to prioritize pandemic readiness, the Coalition for Epidemic Preparedness Innovations (CEPI) has announced a major funding commitment to support Moderna’s investigational mRNA-based pandemic influenza vaccine. CEPI will invest up to $54.3 million to advance a pivotal Phase 3 clinical trial for Moderna’s H5 pandemic influenza vaccine candidate, mRNA-1018, marking a significant step toward potential licensure and improved global preparedness.

Advancing Pandemic Influenza Readiness

The Phase 3 study represents the first pivotal clinical trial of an mRNA-based vaccine specifically targeting pandemic influenza. Designed to begin in early 2026, the trial will evaluate the safety and immunogenicity of Moderna’s H5 vaccine candidate in populations across the United Kingdom and the United States. The study builds on positive Phase 1/2 results that demonstrated rapid and persistent immune responses in healthy adults aged 18 years and older.

If licensed, the vaccine would expand the global portfolio of H5 influenza vaccines with a rapid-response platform capable of addressing emerging pandemic threats. The program also supports CEPI’s 100 Days Mission, which aims to enable the development of safe and effective vaccines within 100 days of identifying a new pandemic pathogen.

Leveraging mRNA Technology for Speed and Scale

Unlike conventional influenza vaccines that rely on virus growth in eggs or cell culture over several months, mRNA vaccines can be designed within days once a virus’s genetic sequence is known and manufactured rapidly at scale. This speed, combined with adaptability and scalability, positions mRNA technology as a critical tool when time-sensitive responses are essential to reduce global health risks.

Commitment to Equitable Access

As part of the agreement with CEPI, Moderna has committed that, if the vaccine is licensed and in the event of an influenza pandemic, 20% of its H5 pandemic vaccine manufacturing capacity will be allocated for timely supply to low- and middle-income countries at affordable pricing. This commitment underscores a shared focus on equitable access alongside scientific advancement.

Next Move Strategy Consulting

The funding initiative is part of CEPI and Moderna’s broader strategic partnership aimed at accelerating epidemic and pandemic vaccine development through Moderna’s mRNA platform. Potential licensure of mRNA-1018 would also leverage data from a pivotal Phase 3 trial of Moderna’s investigational seasonal influenza vaccine, mRNA-1010, further strengthening the clinical foundation of the program.

According to Next Move Strategy Consulting, investments such as CEPI’s support for Moderna’s Phase 3 trial highlight a broader shift within the Vaccines Market toward platform-based technologies that emphasize speed, scalability, and global accessibility. The growing role of mRNA solutions in pandemic preparedness is expected to influence future vaccine development strategies, funding priorities, and public-private collaborations worldwide.

Strengthening the Future of Pandemic Defense

By enabling the advancement of a first-in-class mRNA pandemic influenza vaccine, CEPI’s investment reinforces global efforts to reduce response times and improve vaccine availability during future health emergencies. As pandemic risks persist, initiatives that combine innovative technology with equitable distribution frameworks are set to play a defining role in shaping the next generation of global vaccine preparedness.

Source: Investing News Network

Prepared by: Next Move Strategy Consulting